Session Title

Prostate Cancer Theranostics

Chairpersons
Agata Karolina Pietrzak (Poznań, Poland)
Paolo Turco (Padua, Italy)

Programme

09:45 – 10:15  Patrick Sandach (Essen, Germany): Prostate Cancer Theranostics – what’s its role and why we need it?
10:15 – 10:45  Renata Madru (Kristianstad, Sweden): The utility of Theranostics in various stages of prostate cancer
10:45 – 11:05  Andrea Santos (Lisbon, Portugal): The role of Nuclear Medicine Technologist in Theranostics
11:05 – 11:15  Dmitry Beyder (St. Louis, Missouri, USA): The role of Nuclear Medicine Technologists in Theranostics in the US

Educational Objectives

1. Overview the importance of developing Prostate Cancer Theranostics.
2. Highlight the prostate cancer Theranostics applications and their possible limitations.
3. Present the clinical indications for introducing the prostate cancer Theranostics to the patient.
4. Describe the role of Nuclear Medicine Technologist in the Theranostics medical team.

Summary

Theranostics can be considered an individualized therapeutic protocol, combining diagnosis and therapy, designed accordingly with the patient’s needs. In recent years, Theranostics takes the lead in changing current Nuclear Medicine shape. It is not only modern way of diagnosing and treating cancer patients. It is also a future of the field. Nevertheless, Theranostics, as targeted radionuclide therapy, is complex and demanding.

One of the widely researched Theranostics’ utilities is the prostate cancer patients’ management. Since its introduction, the most studied radioligand seems to be 177Lu-PSMA-617, especially considering metastatic castration-resistant prostate cancer treatment.

Theranostics demands a highly specialized, experienced professionals – an interdisciplinary medical team, including the Nuclear Medicine Technologists. The role of Technologist varies among countries and depends on local and international legislation. Nevertheless, Theranostics team demands appropriately prepared NMT specialist.

Key Words

Oncology, Prostate Cancer, Theranostics